Clinical trials: Methamphetamine Use
Methamphetamine Use Disorder
Accelerated Development of Additive Pharmacotherapy Treatment (ADAPT-2) for Methamphetamine Use Disorder
This is a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy of extended-release naltrexone plus bupropion as a combination pharmacotherapy for methamphetamine use disorder.
- Trial name
- ADAPT-2 (NCT03078075)
- Testing
- Naltrexone: Vivitrol®, Bupropion: Wellbutrin XL®
- Where
- 8 sites in United States
- Volunteers
- 403 people
- Sponsor
- University of Texas Southwestern Medical Center
Opioid Use Disorder, Medication Adherence
MHealth Incentivized Adherence Plus Patient Navigation
Polysubstance use involving opioids and methamphetamine is emerging as a new public health crisis. Patients with opioids and methamphetamine use often experience serious medical complications requiring hospitalization, which…
- Conditions
- Opioid Use Disorder, Medication Adherence, Polysubstance Drug Use (Indiscriminate Drug Use), Methamphetamine-dependence
- Trial name
- MIAPP (NCT06027814)
- Testing
- Patient Navigation and mHealth (PN+mHealth)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Washington
Methamphetamine Abuse, Opioid-use Disorder
Screen, Treat and Retain Meth-using People With Opioid Use Disorders at Methadone Clinics
The investigators propose to develop and evaluate optimal combinations of evidence-based interventions to improve HIV outcomes and reduce methamphetamine use (hereafter: meth use) among people with opioid use disorder who are in…
- Conditions
- Methamphetamine Abuse, Opioid-use Disorder, HIV Seropositivity
- Trial name
- STAR-OM (NCT04706624)
- Testing
- Contingency management (12 weeks), Contingency management (6 weeks), SMS reminders
- Where
- 4 sites in Vietnam
- Volunteers
- 667 people
- Sponsor
- Hanoi Medical University
Substance Use Disorders, Methamphetamine Abuse
A Clinical Study to Evaluate the Safety of CS-1103 in Healthy Participants
The purpose of this Phase 1a study is to evaluate safety, tolerability, and pharmacokinetics (PK) of single, ascending doses of CS-1103, administered by intravenous (IV) infusion in healthy participants.
- Conditions
- Substance Use Disorders, Methamphetamine Abuse, Methamphetamine Intoxication
- Trial name
- NCT06316973
- Testing
- CS-1103, Sterile Saline
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Clear Scientific, Inc.
Methamphetamine Use Disorder
Intermittent Oral Naltrexone Enhanced With an Ecological Momentary Intervention for Methamphetamine-using MSM
This is a double-blind, placebo-controlled phase 2b trial in which 54 MSM who use meth will be randomly assigned (2:1) to receive 12 weeks of as-needed intermittent oral naltrexone 50 mg enhanced with an EMA-informed EMI…
- Trial name
- NCT04791969
- Testing
- Naltrexone Hydrochloride, Ecological Momentary Intervention
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Glenn-Milo Santos
Cocaine Use Disorder, Methamphetamine Abuse
rTMS for Stimulant Use Disorders
The purpose of the study is to determine feasibility of repetitive transcranial magnetic stimulation (rTMS) for individuals with moderate to severe cocaine or methamphetamine use disorder (CUD/MUD).
- Conditions
- Cocaine Use Disorder, Methamphetamine Abuse, Cocaine Dependence, Methamphetamine Dependence
- Trial name
- CTN-0108 (NCT04907357)
- Testing
- rTMS
- Where
- 4 sites in United States
- Volunteers
- 129 people
- Sponsor
- Medical University of South Carolina
Methamphetamine Use Disorder
The Effects of Suvorexant on Sleep, Stress, and Cue-reactivity in Methamphetamine Use Disorder
The purpose of this study is to determine the effects of SUVO on sleep, stress, and cue reactivity/craving and to evaluate the preliminary safety and side effects profile of suvorexant (SUVO)
- Trial name
- NCT05711862
- Testing
- suvorexant (SUVO)
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- The University of Texas Health Science Center, Houston
Methamphetamine Use Disorder
Bupropion in the Treatment of Methamphetamine Dependence
Methamphetamine dependence is a significant drug use disorder in the Midwest. While a number of psychosocial and pharmacological treatments have been studied, no specific treatments for methamphetamine have been identified.
- Trial name
- NCT00572234
- Testing
- bupropion SR
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- University of Nebraska
Methamphetamine Use Disorder
Behavioral Effects of Drugs (Inpatient): 40 [Methamphetamine, Methylphenidate, Duloxetine]
This study will evaluate the behavioral effects of methamphetamine during maintenance on placebo, duloxetine, methylphenidate and duloxetine combined with methylphenidate using sophisticated human laboratory methods.
- Trial name
- NCT04178993
- Testing
- Methamphetamine, Methylphenidate, Duloxetine
- Where
- 2 sites in United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Craig Rush
Cocaine Dependence, Methamphetamine Dependence
Smoking-Cessation and Stimulant Treatment (S-CAST)
The primary objective of this study is to evaluate the impact of substance-abuse treatment as usual plus smoking-cessation treatment (TAU+SCT), relative to substance-abuse treatment as usual (TAU), on drug-abuse outcomes.
- Conditions
- Cocaine Dependence, Methamphetamine Dependence, Nicotine Dependence
- Trial name
- S-CAST (NCT01077024)
- Testing
- Smoking-cessation treatment
- Where
- 12 sites in United States
- Volunteers
- 538 people
- Sponsor
- University of Cincinnati
Substance Use Disorders, Methamphetamine Abuse
Pharmacogenetics of Naltrexone for Stimulant Abuse
This investigation will be the first study assessing genetic modulation of naltrexone's NTX effects upon the abuse liability of a stimulant drug (methamphetamine).
- Trial name
- NCT03226223
- Testing
- Intranasal Methamphetamine
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- New York State Psychiatric Institute
Methamphetamine Use Disorder
Accelerated Development of Additive Pharmacotherapy Treatment for Methamphetamine Use Disorder
The aim of this 2-stage, 3-site study is to investigate the effectiveness and safety of a combination of extended-release depot naltrexone plus extended-release bupropion as a potential pharmacotherapy for methamphetamine (MA)…
- Trial name
- ADAPT (NCT01982643)
- Testing
- naltrexone plus bupropion
- Where
- 3 sites in United States
- Volunteers
- 49 people
- Sponsor
- Walter Ling